Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1248 Monotherapy and with Pembrolizumab in Advanced Solid Tumors
NCT02553499Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Nov 2015
- Primary completion
- Oct 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of MK-1248 in solid tumor (advanced stage) (2 arms), sponsored by Merck & Co. Primary endpoint: Number of Participants Experiencing a Dose-Limiting Toxicity. Started Nov 2015; status: terminated.
02
Drugs
MK-1248
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02553499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02553499.